Cancers, Vol. 11, Pages 1826: Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

Cancers, Vol. 11, Pages 1826: Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials Cancers doi: 10.3390/cancers11121826 Authors: Maennling Tur Niebert Klockenbring Zeppernick Gattenlöhner Meinhold-Heerlein Hussain ：The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted polypeptide ligands. EGFRs are overexpressed in many solid tumors, including breast, pancreas, head-and-neck, prostate, ovarian, renal, colon, and non-small-cell lung cancer. Such overexpression produces strong stimulation of downstream signaling pathways, which induce cell growth, cell differentiation, cell cycle progression, angiogenesis, cell motility and blocking of apoptosis.The high expression and/or functional activation of EGFRs correlates with the pathogenesis and progression of several cancers, which make them attractive targets for both diagnosis and therapy. Several approaches have been developed to target these receptors and/or the EGFR modulated effects in cancer cells. Most approaches include the development of anti-EGFRs antibodies and/or small-molecule EGFR inhibitors. This review presents the state-of-the-art and future prospects of targeting EGFRs to treat breast cancer.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research